A study in the September issue of the Journal of Clinical Sleep Medicine suggests that suvorexant 20/15 mg improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated. The researchers’s concluded the analysis of this study validates orexin receptor antagonism as a novel therapeutic approach for treating insomnia.
Read the article in JCSM: Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials
